Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 1/20 | 0.37 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.37 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.35 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.35 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15437642 | 0.92 | LPAR1 (0.38) | LPAR1LPAR2LPAR3TP53MAPT | |
| SCHEMBL15437917 | 0.92 | MAPT (0.39) | LPAR1LPAR2LPAR3TP53MAPT | |
| SCHEMBL15437305 | 0.90 | LPAR1 (0.38) | LPAR1LPAR2LPAR3MAPTSCN9A | |
| SCHEMBL15437499 | 0.86 | LPAR1 (0.42) | LPAR1LPAR2LPAR3TP53MAPT | |
| SCHEMBL15437826 | 0.86 | LPAR1 (0.42) | LPAR1LPAR2LPAR3TP53MAPT | |
| SCHEMBL15437656 | 0.83 | SCN9A (0.37) | LPAR1LPAR2LPAR3MAPTSCN9A | |
| SCHEMBL15437515 | 0.83 | SCN9A (0.37) | LPAR1LPAR2LPAR3MAPTSCN9A | |
| SCHEMBL4030964 | 0.82 | HDAC3 (0.39) | LPAR1LPAR2LPAR3MAPT | |
| SCHEMBL4032476 | 0.82 | LPAR1 (0.43) | LPAR1LPAR2LPAR3MAPTFTO | |
| SCHEMBL15437474 | 0.81 | SCN9A (0.39) | LPAR1LPAR2LPAR3SCN9ASCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785442-B2 | Compound as antagonist of lysophosphatidic acid receptor, composition, and use thereof | CUREGENIX, INC. (CN) | 2014-07-22 | — | — | US | claimed |
| US-20140031353-A1 | COMPOUND AS ANTAGONIST OF LYSOPHOSPHATIDIC ACID RECEPTOR, COMPOSITION, AND USE THEREOF | CUREGENIX, INC. (CN) | 2014-01-30 | — | — | US | claimed |
| US-8785442-B2 | Compound as antagonist of lysophosphatidic acid receptor, composition, and use thereof | CUREGENIX, INC. (CN) | 2014-07-22 | — | — | US | disclosed |
| US-20140031353-A1 | COMPOUND AS ANTAGONIST OF LYSOPHOSPHATIDIC ACID RECEPTOR, COMPOSITION, AND USE THEREOF | CUREGENIX, INC. (CN) | 2014-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031353-A1 | COMPOUND AS ANTAGONIST OF LYSOPHOSPHATIDIC ACID RECEPTOR, COMPOSITION, AND USE THEREOF | LPAR1, LPAR2, LPAR5 | LPAR1 1/4885LPAR2 2/4885LPAR3 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.